Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population - Results from the PolSenior substudy

Metabolism: Clinical and Experimental

Volumn 63, Issue 11, 2014, Pages 1409-1418

  Olszanecka Glinianowicz, Magdalena ^a   Owczarek, Aleksander ^a   Bozentowicz Wikarek, Maria ^a   Brzozowska, Aniceta ^a   Mossakowska, Małgorzata ^b   Zdrojewski, Tomasz ^c   Grodzicki, Tomasz ^d   Więcek, Andrzej ^a   Chudek, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Aging; Insulin resistance; Nutritional status; Type 2 diabetes; Visfatin

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; INTERLEUKIN 6; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SERUM ALBUMIN; TRIACYLGLYCEROL;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OBESITY; SEX DIFFERENCE; WAIST CIRCUMFERENCE; BLOOD; MULTIVARIATE ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MULTIVARIATE ANALYSIS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NUTRITIONAL STATUS;

EID: 84907968865     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.07.013     Document Type: Article

References (52)

1. A. Fukuhara, M. Matsuda, M. Nishizawa, K. Segawa, M. Tanaka, and K. Kishimoto Visfatin: a protein secreted by visceral fat that mimics the effect of insulin Science 307 2005 426 430
2. V. Varma, A. Yao-Borengasser, N. Rasouli, A.M. Bodles, B. Phanavanh, and M.J. Lee Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation J Clin Endocrinol Metab 92 2007 666 672
3. A. Garten, S. Petzold, A. Barnikol-Oettler, A. Körner, W.E. Thasler, and J. Kratzsch Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes Biochem Biophys Res Commun 391 2010 376 381
4. S.R. Costford, S. Bajpeyi, M. Pasarica, D.C. Albarado, S.C. Thomas, and H. Xie Skeletal muscle NAMPT is induced by exercise in humans Am J Physiol Endocrinol Metab 98 2010 E117 E126
5. H. Xie, S.Y. Tang, X.H. Luo, J. Huang, R.R. Cui, and L.Q. Yuan Insulin-like effects of visfatin on human osteoblasts Calcif Tissue Int 80 2007 201 210
6. B. Samal, Y. Sun, G. Stearns, C. Xie, S. Suggs, and I. McNiece Cloning and charakterisation of the cDNA encoding a novel human pre-B-Cell colony-enhancing factor Mol Cell Biol 14 1994 1431 1437
7. J.R. Revollo, A. Körner, K.F. Mills, A. Satoh, T. Wang, and A. Garten Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme Cell Metab 6 2007 363 375
8. D.G. Haider, G. Schaller, S. Kapiotis, C. Maier, A. Luger, and M. Wolzt The release of the adipocytokine visfatin is regulated by glucose and insulin Diabetologia 49 2006 1909 1914
9. M. Olszanecka-Glinianowicz, P. Kocełak, M. Nylec, J. Chudek, and B. Zahorska-Markiewicz Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome Arch Med Sci 8 2012 214 218
10. A. López-Bermejo, B. Chico-Julià, M. Fernàndez-Balsells, M. Recasens, E. Esteve, and R. Casamitjana Serum visfatin increases with progressive beta-cell deterioration Diabetes 55 2006 2871 2875
11. A.R. Moschen, A. Kaser, B. Enrich, B. Mosheimer, M. Theurl, and H. Niederegger Visfatin and adipocytokine with proinflammatory and immunomodulating properties J Immunol 178 2007 1748 1758
12. M. Olszanecka-Glinianowicz, P. Kocełak, J. Janowska, A. Skorupa, M. Nylec, and B. Zahorska-Markiewicz Plasma visfatin and tumor necrosis factor-alpha (TNF-α) levels in metabolic syndrome Kardiol Pol 69 2011 802 807
13. J. Berndt, N. Klöting, S. Kralisch, S. Kovacs, M. Fasshauer, and M.R. Schön Plasma visfatin concentrations and fat depot - specific mRNA expression in humans Diabetes 54 2005 2911 2916
14. B. Zahorska-Markiewicz, M. Olszanecka-Glinianowicz, J. Janowska, P. Kocełak, E. Semik-Grabarczyk, and M. Holecki Serum concentration of visfatin in obese women Metabolism 56 2007 1131 1134
15. T.D. Filippatos, C.S. Derdemezis, D.N. Kiortsis, A.D. Tselepis, and M.S. Elisaf Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome J Endocrinol Invest 30 2007 323 326
16. U. Unlütürk, A. Harmanci, B.O. Yildiz, and M. Bayraktar Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women Clin Endocrinol (Oxf) 72 2010 469 474
17. A. Jaleel, B. Aheed, S. Jaleel, R. Majeed, A. Zuberi, and S. Khan Association of adipokines with obesity in children and adolescents Biomark Med 7 2013 731 735
18. S. Sandeep, K. Velmurugan, R. Deepa, and V. Mohan Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians Metabolism 56 2007 565 570
19. Y.C. Chang, T.J. Chang, W.J. Lee, and L.M. Chuang The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids Metabolism 59 2010 93 99
20. C. Pagano, C. Pilon, M. Olivieri, P. Mason, R. Fabris, and R. Serra Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans J Clin Endocrinol Metab 91 2006 3165 3170
21. D.A. de Luis, M. Ballesteros, E. Ruiz, C. Muñoz, A. Penacho, and P. Iglesias Visfatin in obese patients, relation with cardiovascular risk factors, a cross sectional study Med Clin (Barc) 137 2011 199 203
22. D.A. de Luis, M.G. Sagrado, R. Aller, R. Conde, and O. Izaola Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle Nutrition 26 2010 1130 1133
23. N. Güdücü, H. ̄sçi, U. Görmüş, A.B. Yiʇiter, and ̄. Dünder Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome J Endocrinol Invest 37 2013 157 161
24. R. Mabrouk, H. Ghareeb, A. Shehab, K. Omar, R.H. El-Kabarity, and D.A. Soliman Serum visfatin, resistin and IL-18 in A group of Egyptian obese diabetic and non-diabetic individuals Egypt J Immunol 20 2013 1 11
25. A. Esteghamati, A. Morteza, A. Zandieh, S. Jafari, M. Rezaee, and M. Nakhjavani The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis J Cardiovasc Transl Res 5 2012 541 546
26. T. Miazgowski, T. Safranow, K. Krzyżanowska-͆winiarska, K. Iskierska, and K. Widecka Adiponectin, visfatin and regional fat depots in normal weight obese premenopausal women Eur J Clin Invest 43 2013 783 790
27. M. Laudes, F. Oberhauser, D.M. Schulte, S. Freude, R. Bilkovski, and J. Mauer Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans Horm Metab Res 42 2010 268 273
28. J.H. Chang, D.M. Chang, K.C. Lin, S.J. Shin, and Y.J. Lee Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review Diabetes Metab Res Rev 27 2011 515 527
29. P. Błędowski, M. Mossakowska, J. Chudek, T. Grodzicki, A. Milewicz, and A. Szybalska Medical, psychological, social, and economic aspects of aging in Poland (PolSenior): research assumptions and objectives Exp Gerontol 46 2011 1003 1009
30. A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro III, and H.I. Feldman A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
31. World Health Organization Technical report series 894: Obesity: Preventing and managing the global epidemic 2000 [Geneva]
32. K.G. Alberti, P. Zimmet, and J. Shaw Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation Diabet Med 23 2006 469 480
33. P. Nadrowski, J. Chudek, T. Grodzicki, M. Mossakowska, M. Skrzypek, and A. Wiecek Plasma level of N-terminal pro brain natriuretic peptide (NT-proBNP) in elderly population in Poland - The PolSenior Study Exp Gerontol 48 2013 852 857
34. B.J. Becker, and M.J. Wu The synthesis of regression slopes in meta-analysis Stat Sci 22 2007 414 429
35. A. Vermeulen, S. Goemaere, and J.M. Kaufman Testosterone, body composition and aging J Endocrinol Invest 22 1999 110 116 [Suppl]
36. A. Tchernof, and E.T. Poehlman Effects of the menopause transition on body fatness and body fat distribution Obes Res 6 1998 246 254
37. A. Shaw, S. Joshi, H. Greenwood, A. Panda, and J.M. Lord Aging of the innate immune system Curr Opin Immunol 22 2010 507 513
38. C.G. Yin, L. Jiang, B. Tang, H. Zhang, Q. Qian, and G.Z. Niu Prognostic significance of plasma visfatin levels in patients with ischemic stroke Peptides 42 2013 101 104
39. K.M. Choi, J.H. Kim, G.J. Cho, S.H. Baik, H.S. Park, and S.M. Kim Effect of exercise training on plasma visfatin and eotaxin levels Eur J Endocrinol 157 2007 437 442
40. J. Shea, E. Randell, S. Vasdev, P.P. Wang, B. Roebothan, and G. Sun Serum retinol-binding protein 4 concentrations in response to short-term overfeeding in normal-weight, overweight, and obese men Am J Clin Nutr 86 2007 1310 1315
41. T.D. Filippatos, V. Tsimihodimos, C.S. Derdemezis, I.F. Gazi, V. Saougos, and D.P. Mikhailidis Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile Nutr Metab Cardiovasc Dis 23 2013 330 336
42. J.A. Seo, E.S. Jang, B.G. Kim, O.H. Ryu, H.Y. Kim, and K.W. Lee Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women Diabetes Res Clin Pract 79 2008 108 111
43. U. Ganter, R. Arcone, C. Toniatti, G. Morrone, and G. Ciliberto Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6 EMBO J 8 1991 3773 3779
44. V. Mohamed-Ali, S. Goodrick, A. Rawesh, D.R. Katz, J.M. Miles, and J.S. Yudkin Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo J Clin Endocrinol Metab 82 1997 4196 4200
45. B.K. Pedersen Muscular interleukin-6 and its role as an energy sensor Med Sci Sports Exerc 44 2012 392 396
46. P.M. Chen, F.M. Chung, D.M. Chang, J.C. Tsai, H.F. Huang, and S.J. Shin Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus J Clin Endocrinol Metab 91 2006 295 299
47. R. Retnakaran, B.S. Youn, Y. Liu, A.J. Hanley, N.S. Lee, and J.W. Park Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study Clin Endocrinol (Oxf) 69 2008 885 893
48. F.O. Gunduz, S.T. Yildirmak, M. Temizel, Y. Faki, M. Cakmak, and M. Durmuscan Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus Diabetes Metab J 35 2011 523 528
49. J. Zhu, M. Schott, R. Liu, C. Liu, B. Shen, and Q. Wang Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes Horm Metab Res 40 2008 801 805
50. R. MacLaren, W. Cui, and K. Cianflone Visfatin expression is hormonally regulated by metabolic and sex hormones in 3 T3-L1 pre-adipocytes and adipocytes Diabetes Obes Metab 9 2007 490 497
51. M. Bala, J. Martin, A. Kopp, F. Hanses, C. Buechler, and A. Schäffler In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-like peptide-1 (GLP-1) J Clin Endocrinol Metab 96 2011 2493 2501
52. A. Körner, A. Garten, M. Blüher, R. Tauscher, J. Kratzsch, and W. Kiess Molecular characteristics of serum visfatin and differential detection by immunoassays J Clin Endocrinol Metab 92 2007 4783 4791